These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 18769302)
1. Tumor-specific activation of prodrugs: is there a role for nuclear medicine? Antunes IF; Haisma HJ; de Vries EF Nucl Med Commun; 2008 Oct; 29(10):845-6. PubMed ID: 18769302 [No Abstract] [Full Text] [Related]
5. The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy. Legigan T; Clarhaut J; Tranoy-Opalinski I; Monvoisin A; Renoux B; Thomas M; Le Pape A; Lerondel S; Papot S Angew Chem Int Ed Engl; 2012 Nov; 51(46):11606-10. PubMed ID: 22996951 [TBL] [Abstract][Full Text] [Related]
6. Paclitaxel prodrugs: toward smarter delivery of anticancer agents. Skwarczynski M; Hayashi Y; Kiso Y J Med Chem; 2006 Dec; 49(25):7253-69. PubMed ID: 17149855 [No Abstract] [Full Text] [Related]
11. Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy. Senter PD FASEB J; 1990 Feb; 4(2):188-93. PubMed ID: 2404820 [TBL] [Abstract][Full Text] [Related]
12. [Peroral fluoropyrimidines in chemotherapy for malignant tumors]. Semiglazova TIu; Gershanovich ML Vopr Onkol; 2001; 47(4):388-95. PubMed ID: 11710276 [No Abstract] [Full Text] [Related]
13. Development of prodrugs for enzyme-mediated, tumor-selective therapy. Yoon KJ; Potter PM; Danks MK Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):107-13. PubMed ID: 15777218 [TBL] [Abstract][Full Text] [Related]
14. Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment. Both GW Curr Opin Mol Ther; 2009 Aug; 11(4):421-32. PubMed ID: 19649987 [TBL] [Abstract][Full Text] [Related]
15. Molecular therapy for cancer. Deisseroth A; Guo D; Wang T; Fujii T; Fu SQ; Cote R; Savinov S; Liu F; Loewe R; Pizzorno G; Austin D; Crystal R; Chung I Cancer J Sci Am; 1998 May; 4 Suppl 1():S5-7. PubMed ID: 9619264 [No Abstract] [Full Text] [Related]
16. Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy. Hayashi JY; Tamanoi F Enzymes; 2017; 42():153-172. PubMed ID: 29054269 [TBL] [Abstract][Full Text] [Related]
17. Recent advances with monoclonal antibody drug targeting for the treatment of human cancer. Koppel GA Bioconjug Chem; 1990; 1(1):13-23. PubMed ID: 2095201 [No Abstract] [Full Text] [Related]
18. Drug metabolism by tumours: its nature, relevance and therapeutic implications. Michael M; Doherty MM Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):783-803. PubMed ID: 18028025 [TBL] [Abstract][Full Text] [Related]
19. Designing anticancer multitarget metal thiosemicarbazone prodrug based on the nature of binding sites of human serum albumin carrier. Yang F; Liang H Future Med Chem; 2018 Aug; 10(16):1881-1883. PubMed ID: 29925269 [No Abstract] [Full Text] [Related]
20. Prodrug-activating systems in suicide gene therapy. Springer CJ; Niculescu-Duvaz I J Clin Invest; 2000 May; 105(9):1161-7. PubMed ID: 10791987 [No Abstract] [Full Text] [Related] [Next] [New Search]